Koers Krebs Biochemicals & Industries Limited
Aandelen
KREBSBIO
INE268B01013
Farmaceutische producten
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
73,01 INR | +2,61% | +3,34% | -6,80% |
Omzet 2022 | 587 mln. 7,04 mln. 6,58 mln. | Omzet 2023 | 521 mln. 6,25 mln. 5,85 mln. | Marktkapitalisatie | 1,22 mld. 14,58 mln. 13,64 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -445 mln. -5,34 mln. -4,99 mln. | Nettowinst (verlies) 2023 | -247 mln. -2,96 mln. -2,77 mln. | EV/omzet 2022 | 7,71 x |
Nettoschuld 2022 | 1,43 mld. 17,15 mln. 16,03 mln. | Nettoschuld 2023 | 1,83 mld. 21,98 mln. 20,55 mln. | EV/omzet 2023 | 5,85 x |
K/w-verhouding 2022 |
-6,94
x | K/w-verhouding 2023 |
-4,92
x | Werknemers | 210 |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 22,45% |
1 dag | +2,61% | ||
1 week | +3,34% | ||
Lopende maand | +19,65% | ||
1 maand | +14,40% | ||
3 maanden | +1,45% | ||
6 maanden | +6,90% | ||
Lopend jaar | -6,80% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jitendra Shah
CEO | Chief Executive Officer | - | 09-11-21 |
Founder | 74 | 02-12-91 | |
Ritesh Jain
DFI | Director of Finance/CFO | - | 03-02-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 67 | 26-09-00 | |
Founder | 74 | 02-12-91 | |
Avinash Ravi
BRD | Director/Board Member | 45 | 01-01-02 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 73,01 | +2,61% | 265 |
25-04-24 | 71,15 | -0,85% | 46 |
24-04-24 | 71,76 | -1,16% | 1 637 |
23-04-24 | 72,6 | +1,30% | 723 |
22-04-24 | 71,67 | +1,44% | 84 |
uitgestelde koers Bombay S.E., 26 april 2024 om 12:00 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-6,80% | 18,88 mln. | |
+19,62% | 43,34 mld. | |
+20,44% | 21,96 mld. | |
+10,86% | 14,09 mld. | |
+13,07% | 13,64 mld. | |
+37,46% | 11,43 mld. | |
-8,59% | 6,86 mld. | |
-0,05% | 6,79 mld. | |
-8,87% | 5,73 mld. | |
+8,46% | 5,22 mld. |